Conventional treatment options, including corticosteroids, intravenous immunoglobulin, or plasma exchange, often fail to treat dysimmune neuropathies, such as chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and monoclonal gammopathy with its subtypes. Therefore, a significant percentage of patients require adjunctive immunosuppressive therapies. Considering that even immunosuppressive agents often are ineffective and/or associated with significant toxicities, the need for the development of safe and effective new treatment options is rising. Currently, several monoclonal antibodies (MAbs) have been tested in open-label small-sized studies or even in single cases so as to establish future directions in the therapy of diseases of the peripheral nervous system (PNS). Rituximab, an MAb targeting against the B cell surface membrane protein CD20, is the most widely used and promising MAb for the treatment of dysimmune neuropathies, especially for those in which immunoglobulin M (IgM) autoantibodies are pathogenetically involved. The efficacy of alemtuzumab, bevacizumab, and etanercept to treat various forms of dysimmune neuropathies is currently under investigation. This review looks critically at recent developments in molecularly targeted therapies for dysimmune neuropathies and also highlights areas of future research to pursue.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2707512 | PMC |
| http://dx.doi.org/10.2119/molmed.2009.00041 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Imaging Tests in the Diagnosis of Dysimmune Neuropathies: A Study of Three Cases.
Med Clin (Barc)
December 2024
Servicio de Neurología, Hospital Universitario de Getafe, Universidad Europea de Madrid, Department of Medicine, Faculty of Biomedical and Health Sciences, Madrid, España. Electronic address:
Immunoglobulin use in neurology: a practical approach.
Pract Neurol
August 2024
UCL Queen Square Institute of Neurology, Faculty of Brain Sciences, University College London, London, UK
Article Synopsis
- Human immunoglobulin (IVIg) is used to treat various immune-mediated neurological disorders, focusing on its effects in both acute inflammatory diseases and chronic disease management.
- The review examines how IVIg works and its evidence in treating conditions like Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) in the UK and Australia.
- It also discusses the pros and cons of IVIg, emphasizes practical aspects like informed consent and risk management, and addresses the careful use of this costly blood product.
Ultrasonographic abnormalities in clinically unaffected nerves of patients with nonvasculitic motor and sensorimotor mononeuropathies.
Muscle Nerve
October 2024
Division of Neurology, Institute of Clinical Neurophysiology, University Medical Center Ljubljana, Ljubljana, Slovenia.
Introduction/aims: Diagnostic criteria for multifocal motor neuropathy (MMN) and multifocal acquired demyelinating sensorimotor neuropathy (MADSAM) require the involvement of at least two peripheral nerves. However, many patients with very similar features have clinical involvement of only a single peripheral nerve, which may preclude their correct diagnosis and treatment. The present study aimed to present a cohort of such patients and discuss the role of ultrasonography (US) in their diagnosis.
View Article and Find Full Text PDFRelapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy: Longitudinal Tracking Through 10 Years Including Pregnancies.
Neurol Neuroimmunol Neuroinflamm
September 2024
From the Department of Neurology (A.L.O.), Massachusetts General Hospital and Harvard Medical School; Department of Pathology (Neuropathology) (A.L.O.), Massachusetts General Hospital; Harvard T.H. Chan School of Public Health & Harvard Medical School (J.A.), Boston; Department of Medical Oncology and Hematology (N.D.), University Hospital Zurich; Department of Neurology (E.P.W.-S.), University of Bern; and Department Neruology (Neurozentrum) (E.P.W.-S.), Luzerner Kantonsspital, Switzerland.
Objectives: To expand understanding of the pathogenesis, presentations, and treatment of initially idiopathic small fiber polyneuropathy (SFN).
Methods: We longitudinally readministered validated metrics to track disease course and treatment responses in a previously healthy woman with acute, postinfectious, skin biopsy-confirmed, idiopathic SFN.
Results: During 5 years, viral respiratory infections triggered 3 separated episodes of acute, disabling burning hand, foot, and face pain (erythromelalgia).
E-Health & Innovation to Overcome Barriers in Neuromuscular Diseases. Report from the 3rd eNMD Congress: Pisa, Italy, 29-30 October 2021.
J Neuromuscul Dis
May 2024
Department of Clinical and Experimental Medicine, Neurological Clinic, University of Pisa, Pisa, Italy.
Neuromuscular diseases (NMDs), in their phenotypic heterogeneity, share quite invariably common issues that involve several clinical and socio-economical aspects, needing a deep critical analysis to develop better management strategies. From diagnosis to treatment and follow-up, the development of technological solutions can improve the detection of several critical aspects related to the diseases, addressing both the met and unmet needs of clinicians and patients. Among several aspects of the digital transformation of health and care, this congress expands what has been learned from previous congresses editions on applicability and usefulness of technological solutions in NMDs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!